ÐÕÃû:¸ßÔóÁ¢ Ö÷ÈÎҽʦ¡¢Ò½Ñ§²©Ê¿
Ö°Îñ:Ïû»¯ÄÚ¿ÆÖ÷ÈÎ
ÅŰà֪ͨ£º¸ßÔóÁ¢Ò½Éú2025Äê7ÔÂ18ÈÕ¡¢19ÈÕÍ£Õ7ÔÂ27ÈÕ³öÕï¡£
¸ßÔóÁ¢£¬ÄУ¬Ö÷ÈÎҽʦ£¬Ò½Ñ§²©Ê¿¡£1983Äê±¾¿Æ±ÏÒµÓÚ¹þ¶û±õÒ½¿Æ´óѧҽѧϵ£¬1989Äê˶ʿ±ÏÒµÓÚºÓ±±Ò½¿Æ´óѧÖ×ÁöËù£¬1995Ä격ʿ±ÏÒµÓÚÉϺ£½»Í¨´óѧҽѧԺ¡£ÔøÏȺóµ£ÈÎÉϺ£½»Í¨´óѧҽѧԺ¸½ÊôµÚÈýÈËÃñÒ½ÔºÏû»¯¿Æ¸±Ö÷ÈΣ¬ÉϺ£ÊÐÆÖ¶«ÐÂÇøÖÜÆÖÒ½ÔºÏû»¯ÄÚ¿ÆÖ÷ÈμæÄÚ¾µÖÐÐÄÖ÷ÈΣ¬ÉϺ£ÊÐÆÖ¶«ÐÂÇøÈËÃñÒ½ÔºÏû»¯ÄÚ¿ÆÖ÷ÈΡ£¸ßÔóÁ¢²©Ê¿´ÓÊÂÏû»¯ÄÚ¿ÆÁÙ´²¡¢½ÌѧºÍ¿ÆÑй¤×÷40ÓàÄ꣬»ýÀÛÁ˷ḻµÄÁÙ´²¾Ñ飬ÓÈÆä¶Ôθ°©Ç°²¡±ä¼°ÔçÆÚÏû»¯µÀÖ×ÁöµÄÕï¶ÏÓëÖÎÁÆÓзḻµÄÁÙ´²¾Ñé;Éó¤ÄÚ¾µÏÂ賦¼²²¡Õï¶ÏºÍθ³¦Ï¢Èâ¼°ÔçÆÚθ°©ÖÎÁÆ;½ºÄÒÄÚ¾µ¼ì²é;ÂýÐÔθÑס¢Î¸Ê³µÀ·´Á÷²¡¡¢Î¸³¦¹¦ÄܺÍÑ×Ö¢¼²²¡µÄÕïÖÎ;ÒÔ¼°Ö¬·¾¸Î¡¢ÂýÐԸβ¡¼°¸ÎÏËά»¯¡¢¸ÎÓ²»¯µÄÕï¶Ï¼°Ò©Îï¸ÉÔ¤ÖÎÁÆ¡£ÏȺó³Ðµ£ÉϺ£ÊпÆÎ¯¡¢½Ìί¿ÎÌ⣬2012Äê²ÎÓëÍê³É½ÌÓý²¿¹ú¼ÒÖØµãʵÑéÊÒ¿ª·Å¿ÎÌ⣬ɳ¼¬ÖÎÁÆÖ¬·¾¸ÎµÄÁÙ´²Ñо¿£¬ÓйØÂÛÖø·¢±íÓÚHepato-gastroenterology¡¢ChineseMedcine¡£ÔÚ¹úÄÚÍâÔÓÖ¾·¢±íÏà¹ØÂÛÖø30ƪ£¬ÆäÖÐ5ƪΪSCIÊÕ¼¡£
1¡¢¶Ôθ°©Ç°²¡±ä¼°ÔçÆÚÏû»¯µÀÖ×ÁöµÈ¼²²¡Õï¶ÏÓëÖÎÁÆÓзḻµÄÁÙ´²¾Ñé¡£
2¡¢ÄÚ¾µÏÂ賦¼²²¡Õï¶ÏºÍθ³¦Ï¢Èâ¼°ÔçÆÚθ°©ÖÎÁÆ;½ºÄÒÄÚ¾µ¼ì²é¡£
3¡¢ÂýÐÔθÑס¢Î¸Ê³µÀ·´Á÷²¡¡¢Î¸³¦¹¦ÄܺÍÑ×Ö¢¼²²¡µÄÕïÖΡ£
4¡¢Ö¬·¾¸Î¡¢ÂýÐԸβ¡¼°¸ÎÏËά»¯¡¢¸ÎÓ²»¯µÄÕï¶Ï¼°Ò©Îï¸ÉÔ¤ÖÎÁƵȡ£
ÏȺó³Ðµ£ÉϺ£ÊпÆÎ¯¡¢½Ìί¿ÎÌ⣬2012Äê²ÎÓëÍê³É½ÌÓý²¿¹ú¼ÒÖØµãʵÑéÊÒ¿ª·Å¿ÎÌ⣬ɳ¼¬ÖÎÁÆÖ¬·¾¸ÎµÄÁÙ´²Ñо¿£¬ÓйØÂÛÖø·¢±íÓÚHepato-gastroenterology¡¢ChineseMedcine¡£ÔÚ¹úÄÚÍâÔÓÖ¾·¢±íÏà¹ØÂÛÖø30ƪ£¬ÆäÖÐ5ƪΪSCIÊÕ¼¡£
µÚÒ»×÷Õß·¢±íÂÛÖø¼°×ÛÊöÈçÏÂ(²¿·Ö)£º
1.¸ÎÓ²±ä»¼ÕßTNFa¡¢IL-6¡¢LN¡¢IVÐͽºÔˮƽ²â¶¨µÄÁÙ´²ÒâÒå.ÁÙ´²ÜöÝÍ£¬1999£¬14(4):147.
2.¸ÉÈÅËØÁªºÏÎÞ»·ÄñÜÕÖÎÁÆÂýÐÔÒÒÐ͸ÎÑ×µÄÁÆÐ§¹Û²ì.賦²¡Ñ§ºÍ¸Î²¡Ñ§ÔÓÖ¾£¬1999£¬8(2):18.
3.¸ÎÏËά»¯µÄѪÇåѧÕï¶Ï¼°ÖÎÁƽü¿ö(×ÛÊö).ÖйúҽѧÎÄÕªÄÚ¿ÆÑ§£¬1999£¬4.288.
4.The effect of retinoic acid on lto cell proliferation and content Of DNA/RNA.World Journal of Gastroenterology. 1999 £¬5.443.
5.ά¼×Ëá¶ÔÖü֬ϸ°ûÔöÖ³ºÍϸ°ûÄÚºËËẬÁ¿µÄÓ°Ïì.ÁÙ´²¸Îµ¨²¡ÔÓÖ¾£¬2000£¬16(4):212.
6.θ°©¼°°©Ç°²¡±ä¶ËÁ£Ã¸»îÐԲⶨ.ÖлªÄÚ¿ÆÔÓÖ¾£¬2000£¬2(4):385.
7.Efect of Sea Buckthorn on liver fibrosis: A clinical study.World Journal of Gastroenterology.2003 ,9.1615.
8.²úϸ°û¶¾ËØÓÄÃÅÂݸ˾úÓëθ°©·¢Éú¹ØÏµµÄÑо¿.ÖлªÏû»¯ÄÚ¾µÔÓÖ¾£¬2004£¬21(6):395.
9.Ê÷ͻϸ°û¹¦ÄÜÓëÒÒÐ͸ÎÑײ¡¶¾¸ÐȾµÄÂýÐÔ»¯Ñо¿½øÕ¹.¹úÍâҽѧ:Á÷Ðв¡´«È¾²¡·Ö²á£¬2005.32:299.
10. Clinical significances of changes in tumor markers£¬extracellular matrix£¬MMP-9 and VEGF in patients with gastric carcinoma.Hepato-Gastroerterology 2007£¬75(10):2284.
11.θð¤Ä¤³¦ÉÏÆ¤»¯Éú¡¢Î¸ÉÏÆ¤ÄÚÁö±äÓëθ°©µÄ×éÖ¯·¢Éú.ÊÀ½ç»ªÈËÏû»¯ÔÓÖ¾£¬2011£¬19:1981.
12 ɳ¼¬ÖÎÁƷѾƾ«ÐÔÖ¬·¾¸ÎµÄÁÙ´²Ñо¿.ÏÖ´úÖÐÎ÷Ò½½áºÏÔÓÖ¾£¬2012£¬21:1485.
13.½ºÄÒÄÚ¾µ¼ì²é42Àý·ÖÎö.ºÚÁú½Ò½Ò©£¬2016£¬306-309.
14.Clinical evaluation of hepatic fibrosis in Chineses patients with nonalcoholic fatty liver disease with FibroScan. Chineses Medcine£¬ 2015£¬6£¬115-123.
15.The effect of sea buckthorn therapy in patients with nonalcoholic fatty liver Disease.Chineses Medcine£¬2014£¬5£¬223-230.
16.Clinical and Experimental Study on Probiotics in the Treatment of Constipation Type lrritable Bowel Syndrome.Biomarkers and Applications£¬2019.3:135-139.
ÎÂܰÌáʾ£ºÌÈÈôÄúÏëÁ˽â¸ü¶à¹ØÓÚÉϺ£À¶Ê®×ÖÄÔ¿ÆÒ½ÔºµÄ×îÐÂÐÅÏ¢£¬Äú¿ÉÒÔ²¦´òÎÒÔº½¡¿µÈÈÏß 021-64879999 »òÇëÔÚÏß×Éѯ¿Í·þ£¬ÎÒÃÇÌṩʵʱҽѶ¡¢¼²²¡×Éѯ¡¢×¨¼ÒÔ¤Ô¼µÈ·þÎñ¡£¿´²¡ÕÒר¼Ò£¬Ô¤Ô¼ÕÒ¿Í·þ£¬ÄÜΪÄúµÄ½¡¿µ±£¼Ý»¤º½ÊÇÎÒÃÇ×î´óµÄÈÙÐÒ£¬¸ÐлÄúµÄÖ§³ÖÓëÐÅÈΣ¡
ÐÄϵְ¹¤°ìʵÊ£¬¹âÓ°Á÷·¼Å¯ÈËÐÄ£¡...¡¾Ïêϸ¡¿